5:45 PM
 | 
Jun 26, 2013
 |  BC Extra  |  Financial News

Regulus planning follow-on, adds options to Sanofi deal

MicroRNA company Regulus Therapeutics Inc. (NASDAQ:RGLS) proposed late Wednesday to raise up to $57.5 million in a follow-on underwritten by Lazard; Cowen; BMO Capital Markets; Needham; and Wedbush.

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >